Logo image of IVVD

INVIVYD INC (IVVD) Stock Fundamental Analysis

NASDAQ:IVVD - Nasdaq - US00534A1025 - Common Stock - Currency: USD

0.94  -0.22 (-18.97%)

After market: 0.9499 +0.01 (+1.05%)

Fundamental Rating

2

IVVD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While IVVD seems to be doing ok healthwise, there are quite some concerns on its profitability. IVVD has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IVVD has reported negative net income.
In the past year IVVD has reported a negative cash flow from operations.
IVVD Yearly Net Income VS EBIT VS OCF VS FCFIVVD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

IVVD has a worse Return On Assets (-139.04%) than 83.21% of its industry peers.
IVVD's Return On Equity of -270.72% is on the low side compared to the rest of the industry. IVVD is outperformed by 73.04% of its industry peers.
Industry RankSector Rank
ROA -139.04%
ROE -270.72%
ROIC N/A
ROA(3y)-62.07%
ROA(5y)N/A
ROE(3y)-73.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVVD Yearly ROA, ROE, ROICIVVD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60 -80 -100

1.3 Margins

IVVD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVVD Yearly Profit, Operating, Gross MarginsIVVD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for IVVD has been increased compared to 1 year ago.
There is no outstanding debt for IVVD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IVVD Yearly Shares OutstandingIVVD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M 100M
IVVD Yearly Total Debt VS Total AssetsIVVD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -10.76, we must say that IVVD is in the distress zone and has some risk of bankruptcy.
IVVD's Altman-Z score of -10.76 is on the low side compared to the rest of the industry. IVVD is outperformed by 75.89% of its industry peers.
IVVD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.76
ROIC/WACCN/A
WACCN/A
IVVD Yearly LT Debt VS Equity VS FCFIVVD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

IVVD has a Current Ratio of 1.92. This is a normal value and indicates that IVVD is financially healthy and should not expect problems in meeting its short term obligations.
IVVD has a worse Current ratio (1.92) than 77.32% of its industry peers.
A Quick Ratio of 1.58 indicates that IVVD should not have too much problems paying its short term obligations.
IVVD's Quick ratio of 1.58 is on the low side compared to the rest of the industry. IVVD is outperformed by 81.07% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.58
IVVD Yearly Current Assets VS Current LiabilitesIVVD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for IVVD have decreased strongly by -41.01% in the last year.
EPS 1Y (TTM)-41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IVVD will show a very strong growth in Earnings Per Share. The EPS will grow by 34.32% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.6%
EPS Next 2Y43.66%
EPS Next 3Y34.2%
EPS Next 5Y34.32%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IVVD Yearly Revenue VS EstimatesIVVD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IVVD Yearly EPS VS EstimatesIVVD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IVVD. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 8.13, which indicates a very decent valuation of IVVD.
97.68% of the companies in the same industry are more expensive than IVVD, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.44, IVVD is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.13
IVVD Price Earnings VS Forward Price EarningsIVVD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVVD Per share dataIVVD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

IVVD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IVVD's earnings are expected to grow with 34.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.66%
EPS Next 3Y34.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IVVD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVIVYD INC

NASDAQ:IVVD (3/3/2025, 8:00:02 PM)

After market: 0.9499 +0.01 (+1.05%)

0.94

-0.22 (-18.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-27 2025-03-27/amc
Inst Owners79.43%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change0%
Market Cap112.44M
Analysts80
Price Target6.8 (623.4%)
Short Float %6.88%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.6%
Min EPS beat(2)-48.15%
Max EPS beat(2)-5.04%
EPS beat(4)1
Avg EPS beat(4)-22.05%
Min EPS beat(4)-55.17%
Max EPS beat(4)20.17%
EPS beat(8)3
Avg EPS beat(8)-7.09%
EPS beat(12)6
Avg EPS beat(12)-0.48%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-61.11%
Min Revenue beat(2)-66.54%
Max Revenue beat(2)-55.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)13.23%
PT rev (3m)-11.23%
EPS NQ rev (1m)23.08%
EPS NQ rev (3m)-42.86%
EPS NY rev (1m)4.52%
EPS NY rev (3m)-6.73%
Revenue NQ rev (1m)10.3%
Revenue NQ rev (3m)35.67%
Revenue NY rev (1m)0.57%
Revenue NY rev (3m)-86.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.13
P/S 9.72
P/FCF N/A
P/OCF N/A
P/B 1.35
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)0.12
Fwd EY12.3%
FCF(TTM)-1.61
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS0.1
BVpS0.7
TBVpS0.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -139.04%
ROE -270.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.07%
ROA(5y)N/A
ROE(3y)-73.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.89%
Cap/Sales 1.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.58
Altman-Z -10.76
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.67%
EPS Next Y16.6%
EPS Next 2Y43.66%
EPS Next 3Y34.2%
EPS Next 5Y34.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.04%
EBIT Next 3Y23.24%
EBIT Next 5Y17.96%
FCF growth 1Y21.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.84%
OCF growth 3YN/A
OCF growth 5YN/A